The results of the CRIB-2 trial, which show that the mineralocorticoid receptor blocker (MRB) spironolactone improves left ventricular mass and aortic stiffness in patients with early stage chronic kidney disease (CKD), provide impetus for large-scale clinical trials to evaluate the effects of this strategy on clinical outcomes. The optimum choice of MRB and its dose, however, remain uncertain given the potential risk of hyperkalemia in patients with CKD.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Edwards, N. C., Steeds, R. P., Stewart, P. M., Ferro, C. J. & Townsend, J. N. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J. Am. Coll. Cardiol. 54, 505–512 (2009).
Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709–717 (1999).
Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309–1321 (2003).
Sowers, J. R., Whaley-Connell, A. & Epstein, M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern. Med. 150, 776–783 (2009).
Epstein, M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am. J. Med. 119, 912–919 (2006).
Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543–551 (2004).
Preston, R. A. et al. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. Hypertension 53, 754–760 (2009).
McManus, F., McInnes, G. T. & Connell, J. M. Drug insight: eplerenone, a mineralocorticoid-receptor antagonist. Nat. Clin. Pract. Endocrinol. Metab. 4, 44–52 (2008).
Kolfoph, P. et al. Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive hypertension [abstract P754]. Eur. Heart J. 27 (Suppl. 1), 110 (2006).
Evaluation of RLY5016 in heart failure patients (Pearl-HF). ClinicalTrials.gov: a service of the US NIH, [online] (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B. Pitt has acted as a consultant for AstraZeneca, Bayer, BG Medicine, Daiichi Sankyo, Forest Laboratories, GE Healthcare Kaperio, Merck & Co., Nile Therapeutics, Novartis, ONO Pharmaceutical, Paracor Medical, Pericor Therapeutics, Pfizer, Relypsa, Schering-Plough, and Takeda. He has received research grants from Abbott, Bayer, Biomarin, and Medtronic, and has stock options with BG Medicine, Nile Therapeutics, Paracor Medical, and Relypsa.
Rights and permissions
About this article
Cite this article
Pitt, B. Cardiovascular effects of aldosterone blockade in CKD. Nat Rev Cardiol 6, 679–680 (2009). https://doi.org/10.1038/nrcardio.2009.175
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2009.175
